Sofetabart Mipitecan
Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.
Overview
Sofetabart Mipitecan (LY4170156) is an antibody-drug conjugate developed by Eli Lilly and. Its target is Folate receptor alpha (the sponsor names folate receptor alpha). The sponsor states: An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07213804 (A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer), in ovarian cancer. The largest, NCT07213804, plans to enrol 1630 participants with primary completion expected 2028-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Sofetabart Mipitecan" OR ABSTRACT:"Sofetabart Mipitecan" OR TITLE:"LY4170156" OR ABSTRACT:"LY4170156" OR TITLE:"Sofe-M" OR ABSTRACT:"Sofe-M") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sofetabart Mipitecan, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentFarletuzumab-exatecan
Shares Folate receptor alpha and the tags pipeline, ctgov-ingest.
- TreatmentChiauranib
Shares Folate receptor alpha, Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentVepugratinib
Shares Eli Lilly (incl. Loxo) and the tags pipeline, ctgov-ingest.
- TreatmentTersolisib
Shares Eli Lilly (incl. Loxo) and the tags pipeline, ctgov-ingest.
- TreatmentIMP4927
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentOregovomab
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentPalacaparib
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD5335
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.